BGMSHIGH SIGNALFINANCIAL10-K

BGMS executed a dramatic share consolidation (reducing outstanding shares from 207M to 5.5M) while substantially improving its financial position through reduced liabilities and operating losses.

The massive 97% reduction in share count suggests a reverse stock split aimed at addressing compliance issues or improving share price perception. The company appears to have restructured its balance sheet meaningfully, converting from a net liability position to positive equity while maintaining similar asset levels. This transformation indicates either debt restructuring, equity infusion, or conversion of liabilities to equity.

Comparing 2026-03-30 vs 2025-04-02View on EDGAR →
FINANCIAL ANALYSIS

BGMS doubled its total assets to $8.2M while dramatically reducing total liabilities from $6.3M to $1.3M, creating a substantially improved balance sheet position. Operating performance showed meaningful improvement with net losses narrowing considerably and R&D expenses declining significantly, though the company remains unprofitable. The financial restructuring, combined with the extreme share consolidation, suggests BGMS underwent a major corporate reorganization during this period.

FINANCIAL STATEMENT CHANGES
Total Assets
Balance Sheet
+99.9%
$4.1M$8.2M

Asset base grew 99.9% — expansion through organic growth, acquisitions, or capital deployment.

R&D Expense
P&L
-87.3%
$6.7M$848K

R&D spending cut 87.3% — could signal cost discipline or concerning reduction in innovation investment.

Current Liabilities
Balance Sheet
-78.7%
$6.3M$1.3M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-78.6%
$6.3M$1.3M

Liabilities reduced 78.6% — deleveraging improves balance sheet strength and financial flexibility.

Interest Expense
P&L
-75.7%
$177K$43K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Net Income
P&L
+73.3%
-$11.2M-$3.0M

Net income grew 73.3% — bottom-line growth signals improving overall business health.

Current Assets
Balance Sheet
+70.3%
$3.7M$6.3M

Current assets grew 70.3% — improving short-term liquidity or inventory/receivables build.

Operating Cash Flow
Cash Flow
+40.3%
-$8.0M-$4.8M

Operating cash flow surged 40.3% — exceptional cash generation, highest quality earnings signal.

Operating Income
P&L
+29.8%
-$12.0M-$8.4M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

SG&A Expense
P&L
-19.7%
$6.7M$5.4M

SG&A reduced 19.7% — improved cost efficiency or headcount reduction improving operating margins.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-04-02
ADDED
Employer of Incorporation or Organization) Identification No.) Level 10, Tower 11 , Avenue 5, No.
7262(b)) by the registered public accounting firm that prepared or issued its audit report.
As of March 24, 2026, there were 5,519,456 shares of the registrant s common stock outstanding.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 93 Item 13.
Below is a summary of the principal risk factors that may affect our business, financial condition and results of operations.
+7 more — sign up free →
REMOVED
Cyclacel Pharmaceuticals, Inc._December 31, 2024 0001130166 false 2024 FY Cyclacel Pharmaceuticals, Inc.
Employer Identification No.) Level 10, Tower 11 , Avenue 5, No.
7262(b)) by the registered public accounting firm that prepared or issued its audit report .
As of March 27, 2025, there were 207,336,389 shares of the registrant s common stock outstanding.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 116 I tem 13.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →